Link To ::
Topics
TACT: Allegations, OHRP Investigation, Background, and Media Coverage
Gervasio Lamas, M.D. CAM Collaboration in TACT (Cancer Researchers and CAM Practitioners: Fostering Collaboration, Office of Cancer Complementary and Alternative Medicine, National Cancer Institute) 2007-10-22[starts 389]: http://videocast.nih.gov/summary.asp?Live=9394&bhcp=1
Atwood KC, Woeckner E, Baratz RS, Sampson WI. Why the NIH Trial to Assess Chelation Therapy (TACT) Should Be Abandoned. Medscape J Med 2008;10(5):115. Accessed on 2008-06-11 at: http://www.medscape.com/viewarticle/570625 (Requires free registration)
TACT Trial Website (contains study documents current to August 2008): http://www.chelationwatch.org/s/tact/index.html
Buchanan LR. Office for Human Research Protections Letter to Kimball C. Atwood, M.D. 2009-11-06: http://www.circare.org/tact/ohrp_20091106.pdf
Buchanan LR. Office for Human Research Protections Determination Letter to Mount Sinai Medical Center. 2009-10-30: http://www.hhs.gov/ohrp/detrm_letrs/YR09/oct09a.pdf
Buchanan LR.Office for Human Research Protections Determination Letter to Mount Sinai Medical Center, University of Miami, and Duke University Health System. 2009-05-27: http://www.hhs.gov/ohrp/detrm_letrs/YR09/may09b.pdf
TACT: AHA Meeting Presentations & Media Coverage November 2012
Alternative therapy produces intriguing results in some heart patients but many questions remain American Heart Association Press Release 2012-11-04: http://newsroom.heart.org/pr/aha/alternative-therapy-produces-intriguing-240492.aspx
The Trial to Assess Chelation Therapy (TACT) Gervasio Lamas, M.D. AHA Slides 2012-11-04: http://www.circare.org/tact/LBCT01-04-TACT-Slides-11-2-12 copy.pdf
Trial to Assess Chelation Therapy (TACT) Quality of Life Outcomes Daniel Mark, M.D., M.P.H. AHA Slides 2012-11-04: http://www.circare.org/tact/LBCT02-03-TACTQoL-slides-10-26-12.pdf
Trial to Assess Chelation Therapy AHA 2012 LBT Commentary Paul W. Armstrong, M.D. 2012-11-04: http://www.circare.org/tact/TACT additionnaal slides.pdf
Clinical Implications of CPORT-E, TACT and FREEDOM Trials David O. Williams, M.D. AHA Slides 2012-11-04: http://www.circare.org/tact/TACT mmore slides.pdf
Doctors Debate Value of 'Fringe' Heart Treatment Marilynn Marchione AP 2012-11-04: http://www.salon.com/2012/11/05/doctors_debate_value_of_fringe_heart_treatment/
Doctors Dismiss Study That Says Chelation Helps Heart Patients Matthew Herper Forbes 2012-11-04: http://www.forbes.com/sites/matthewherper/2012/11/04/civil-war-a-study-says-chelation-might-help-heart-patients-but-doctors-dont-believe-it/
Study finds heart chelation therapy effective but raises questions. Elizabeth Cohen and John Bonifield CNN 2012-11-06: http://www.cnn.com/2012/11/04/health/chelation-heart-study/index.html?hpt=hp_t3
The Trial to Assess Chelation Therapy: Equivocal as Predicted Kim Atwood, M.D. Science Based Medicine 2012-11-04: http://www.sciencebasedmedicine.org/index.php/the-trial-to-assess-chelation-therapy-equivocal-as-predicted/
Researchers raise concerns over chelation heart study Liz Szabo USA Today 2012-11-04: http://www.usatoday.com/story/news/nation/2012/11/04/chelation-therapy-heart-disease/1678251/
Troubled study at heart of therapy debate. Trine Tsoudoros Chicago Tribune 2011-12-12: http://articles.chicagotribune.com/2011-12-12/health/ct-met-nccam-tact-trial-20111212_1_chelation-clinical-trials-study-drug
Study's doctors have had their share of troubles. Trine Tsoudoros Chicago Tribune 2011-12-12: http://articles.chicagotribune.com/2011-12-12/health/ct-met-tact-sidebar-20111212_1_chelation-tact-cancer-patients
Lamas GA. et al. Design of the Trial to Assess Chelation Therapy (TACT) Am Heart J 2012;163:7-12 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243954/
Heart patients in big alternative medicine study not fully told of risks, probe finds. Marilynn Marchione. AP 2009-07-02: http://www.nbcnews.com/id/31715589/ns/health-heart_health/t/heart-attack-survivors-not-told-study-dangers/
Enrollment Resumes for CHD Chelation-Therapy Trial. Steve Stiles. Medscape/Heartwire. 2009-06-12. Accessed on 2009-07-01 at: http://www.medscape.com/viewarticle/704375
Government probes chelation-heart disease study. Marilynn Marchione. AP. 2008-09-25: http://www.pantagraph.com/news/government-probes-chelation-heart-disease-study/article_7a6c3f1a-7e2d-5b8f-b4cb-1c3047431763.html
Mitka M. JAMA. Chelation Therapy Trials Halted. 2008;300(19):2236. Accessed on 2009-03-09 at: http://jama.ama-assn.org/cgi/content/full/300/19/2236
Hall H. Tactless About TACT: Critiques Without Substance Should Be Abandoned. Science-Based Medicine Blog. Accessed on 2009-07-01 at: http://www.sciencebasedmedicine.org/?p=534
Clay B. Study of Chelation Therapy Should Not Be Abandoned. Journal of American Physicians and Surgeons 2009;14(2):51-57. Accessed on 2009-07-01 at: http://www.jpands.org/vol14no2/clay.pdf
Atwood KA. The TACT is at least as Bad as We Predicted. Science Based Medicine. Accessed on 2008-06-11 at: http://www.sciencebasedmedicine.org/?p=132
Trial to Assess Chelation Therapy (TACT) U01AT001156 FCOI Nahin, R. Letter to Paul Katz, M.D., Mount Sinai Medical Center RE: MSMC Financial Conflict of Interest Policies 2004-03-23: http://www.circare.org/tact/U01AT001156_fcoi_20040323.pdf
Trial to Assess Chelation Therapy (TACT) 7U01HL092607 Audit Response Lamas, G.A. Memo RE: Medicaid Audit of TACT Investigator Dr. Zbigniew Grudzien, M.D. 2011-03-14: http://www.circare.org/tact/7U01HL092607_audit_response_20110314.pdf
Trial to Assess Chelation Therapy (TACT) AT001156 Financial Status Reports 2003-2009: http://www.circare.org/tact/at001156_tact_fsrs_2003_2009.pdf
Trial to Assess Chelation Therapy (TACT) U1AT001156A PMS Report 2002-2009 (2011-08-11): http://www.circare.org/tact/u1at001156a_tactpms_report_2002_2009.pdf
Trial to Assess Chelation Therapy (TACT) U1HL092607A PMS Report 2010 (2011-08-11): http://www.circare.org/tact/u1hl092607a_tact_pmsreport_2010.pdf
Trial to Assess Chelation Therapy (TACT) U1HL092607B PMS Report 2011 (2011-08-11): http://www.circare.org/tact/u1hl092607b_tact_pmsreport_2011.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Progress Reports Part 1 2012-02-19: http://www.circare.org/tact/tact_progressreports_pt1.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Progress Reports Part 2 2012-02-19: http://www.circare.org/tact/tact_progressreports_pt2.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Progress Reports Part 3 2012-02-19: http://www.circare.org/tact/tact_progressreports_pt3.pdf
Smaller files:
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Grant Progress Report 2003-07-18: http://www.circare.org/tact/tact-gpr_20030718.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Grant Progress Report 2003-12-01: http://www.circare.org/tact/tact-gpr-20031201_.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Grant Progress Report 2004-12-28: http://www.circare.org/tact/tact-gpr_20041228.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Grant Progress Report 2005-12-28: http://www.circare.org/tact/tact-gpr_20051228.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Grant Progress Report 2008-01-30: http://www.circare.org/tact/tact-gpr_20080130.pdf
TACT Study Suppliers: Criminal Litigation
Pharmacy Owner Indicted, Arrested for Defrauding Medicaid. U.S. Department of Justice Press Release. 2008-05-29. Accessed on 2009-02-03 at: http://web.archive.org/web/20090422082320/http://www.justice.gov/usao/fls/PressReleases/080509-02.html
Marilyn Garcia Ferro Criminal No. 08CR20403 USDC FLSD Indictment 2008-05-13: http://www.circare.org/lex/08cr20403_20080513.pdf
Marilyn Garcia Ferro Criminal No. 08CR20403 USDC FLSD Judgment 2009-02-04: http://www.circare.org/lex/08cr20403_20090204.pdf
Professional Disciplinary Actions
Marilyn Garcia-Ferro, RPh State of Florida Board of Pharmacy Final Order 1998-08-31: http://www.circare.org/tact/garcia-ferro_199808431.pdf
Accu-Care Services, Inc. State of Florida Board of Pharmacy Final Order 1998-08-31: http://www.circare.org/tact/accu-careservices_19980831.pdf
Two Pharmed Directors Charged in Wire Fraud Conspiracy and Tax Evasion Scheme. U.S. Department of Justice Press Release. 2008-07-22. Accessed on 2009-02-03 at: http://www.usdoj.gov/usao/fls/PressReleases/080722-01.html
Two Pharmed Directors Plead Guilty to Wire Fraud Conspiracy and Tax Evasion Scheme. U.S. Department of Justice Press Release 2008-09-28: http://www.justice.gov/tax/usaopress/2008/txdv08_080912-01.pdf
Soaring rise, rapid fall for Pharmed. John Dorschner. The Miami Herald. 2008-02-03: http://www.miamiherald.com/business/v-print/story/612878.html
TACT Study Drug Edetate Disodium
FR Vol. 73 No. 114 2008-06-12. Hospira, Inc., et al.; Withdrawal of Approval of One New Drug Application and Two Abbreviated New Drug Applications. Food and Drug Administration. 33440-33441. Accessed on 2009-02-04 at: http://www.fda.gov/OHRMS/DOCKETS/98fr/E8-13273.htm
Information on Edetate Disodium (marketed as Endrate and generic products). U.S. Food and Drug Administration. 2008-01-16. Accessed on 2009-07-01 at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113736.htm
FDA Public Health Advisory Edetate Disodium (marketed as Endrate and generic products). U.S. Food and Drug Administration. 2008-01-16. Accessed on 2009-07-01 at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051138.htm
Questions and Answers on Edetate Disodium (marketed as Endrate and generic products). U.S. Food and Drug Administration. 2008-01-16. Accessed on 2009-07-01 at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113738.htm
National Supply Service Center (NSSC) Important Notice Market Withdrawal. Recall: 2008-008. Class of Recall: Not Yet Classified-Hospital Level. Supplier: Hospira Worldwide Inc. #00108. Product Description: Endrate AMP 150mg 20ml 25's. 2008-01-16. Accessed on 2008-03-29 at: http://www.ihs.gov/NonMedicalPrograms/NSSC/index.asp?module=alerts&opt=2008-008
Endrate™ Edetate Disodium Injection USP. Professional Prescribing Information. Abbott Hospital Products. Available from http://www.circare.org/foia2/endrate_ppi.pdf
Jorgensen C, Pentel P, Somerville, J, Gruber LR. Ad Hoc Committee on Chelation Therapy, Hennepin County Medical Society. Chelation therapy for the treatment of atherosclerosis: An appraisal. July, 1983. Accessed on 2007-04-02 at: http://www.circare.org/tact/ct_hennepincountymedicalsociety_198307.pdf
Nightingale SL. The FDA and Drug Uses: Reprise. JAMA. 1985;253:632. Accessed on 2006-11-09 at: http://www.circare.org/foia2/nightingale_jama1985.pdf
Connock M, Wilson J, Song F, Hyde C, Meads C. Chelation therapy for Intermittent Claudication and Coronary Heart Disease. Report 33, July 2002, WMHTAC, Department of Public Health & Epidemiology, University of Birmingham. ISBN: 07044 2343X: http://www.birmingham.ac.uk/Documents/college-mds/haps/projects/WMHTAC/REPreports/2002/chelation.pdf
Deaths Associated with Hypocalcemia from Chelation Therapy — Texas, Pennsylvania, and Oregon, 2003–2005. MMWR Weekly. March 3, 2006 / 55(08);204-207. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm?s_cid=mm5508a3_e. Accessibility verified 2006-03-02.
Wetherall R. FDA Office of Legislative Services. Letter to the Honorable Robert P. Griffin re: disodium EDTA and constituents' correspondence with FDA. 1977-07-13. Available from http://www.circare.org/foia2/fda_griffin19770713letter.pdf
American College for Advancement in Medicine (ACAM)
American College for Advancement in Medicine, File No. 962 3147, Docket No. C-3882. Federal Trade Commission (complaint and settlement for false advertising): http://www.ftc.gov/os/caselist/c3882.shtm
Gordon GF. American Academy of Medical Preventics An Open Letter to Those Persons Interested in Chelation Therapy. Undated. Accessed on 2007-05-01 at: http://www.circare.org/tact/aamp_openletter.pdf
American College for Advancement in Medicine. American College for Advancement in Medicine Institutional Review Board Investigational Project Guidelines. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_projectguidelines.pdf. November, 1993. Accessibility verified October 27, 2005.
American College for Advancement in Medicine. American College for Advancement in Medicine Institutional Review Board Sample Protocol. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_sampleprotocol.pdf. November 10, 1994. Accessibility verified October 27, 2005.
Miranda RA. American College for Advancement in Medicine Letter to investigators. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acam_irbdisbanded20011127.pdf. November 27, 2001. Accessibility verified October 27, 2005.
Diehl R. American College for Advancement in Medicine Institutional Review Board letter addressed to Eleazar M. Kadile, MD. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_kadile19940722.pdf. July 22, 1994. Accessibility verified October 27, 2005.
Mossburg K. American College for Advancement in Medicine Institutional Review Board Letter addressed to Eleazar M. Kadile, MD. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_kadile19941110.pdf. November 10, 1994. Accessibility verified October 27, 2005.
Azzaro L. American College for Advancement in Medicine Institutional Review Board Letter addressed to Eleazar M. Kadile, MD. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_kadile20000214.pdf. February 14, 2000. Accessibility verified October 27, 2005.
Shaw EA. American College for Advancement in Medicine Institutional Review Board Letter to all participants in the ACAM IRB review process. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_memo19950502.pdf. May 2, 1995. Accessibility verified October 27, 2005.
Miranda RA. American College for Advancement in Medicine Institutional Review Board Letter to all investigators with current active ACAM IRB reviewed study protocols. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_memo19960524.pdf. May 24, 1996. Accessibility verified October 27, 2005.
Miranda RA. American College for Advancement in Medicine Institutional Review Board Protocol Monitoring Report Forms addressed to Eleazar M. Kadile, MD. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamirb_monitoringreports.pdf. November 29, 1995 — February 21, 2001. Accessibility verified October 27, 2005.
Chappell LT. Study Protocol, Coronary Artery Risk Factor Reduction Registry. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamedtaregistry_protocol.pdf. October 10, 1999. Accessibility verified October 27, 2005.
Chappell LT. Consent Form, Coronary Artery Risk Factor Reduction Registry. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/acamedtaregistry_consentform.pdf. Undated. Accessibility verified October 27, 2005.
Patient Consent Forms for EDTA Chelation Therapy
Chappell LT. Agreement Concerning Chelation Therapy. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/chappell_ctagreement.pdf. September 6, 2002. Accessibility verified October 27, 2005.
McDonagh EW. Agreement Concerning Chelation Therapy. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/mcdonagh_ctagreement.pdf. November 11, 1997. Accessibility verified October 27, 2005.
Great Lakes College of Clinical Medicine (GLCCM)
Chappell LT. Curriculum Vitae. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/cv_ltchappell2002.pdf. 2002. Accessibility verified October 27, 2005.
Hanks J. Principles of Ethics for Members of the Great Lakes College of Clinical Medicine. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/glccm_ethicsformembers.pdf. January, 2001. Accessibility verified October 27, 2005.
Chappell LT, Carter JP. Great Lakes College of Clinical Medicine Institutional Review Board Letters of Termination for Project M021, EDTA Chelation and Coronary Artery Disease Patient Registry, addressed to L. Terry Chappell MD, Jack Young MD, James Carter MD, and Tammy Born DO. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/glccmirb_m021termination.pdf. January 15, 2001. Accessibility verified October 27, 2005.
Kotsanis CA. Letter to Betsy Angus and L. Terry Chappell, MD, Great Lakes College of Clinical Medicine Institutional Review Board. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/kotsanis_irb20000626.pdf. June 26, 2000. Accessibility verified October 27, 2005.
Musnick D. Proposal for an IRB. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/musnick_irb.pdf. Undated. Accessibility verified October 27, 2005.
Masiello SA. FDA Letter addressed to Barbara Grunewald, Great Lakes College of Clinical Medicine. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/foia2/fda_glccm20010102.pdf. January 2, 2001. Accessibility verified October 27, 2005.
Great Lakes College of Clinical Medicine. Great Lakes College of Clinical Medicine Institutional Review Board Investigational Project Guidelines. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/glccmirb_projectguidelines.pdf. March 2000. Accessibility verified October 27, 2005.
Additional information about the Great Lakes College of Clinical Medicine and the Great Lakes College of Clinical Medicine Institutional Review Board: http://www.circare.org/foia2/docs.htm
NCCAM NIH TACT Documents
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Progress Reports Part 1 2012-02-19: http://www.circare.org/tact/tact_progressreports_pt1.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Progress Reports Part 2 2012-02-19: http://www.circare.org/tact/tact_progressreports_pt2.pdf
Trial to Assess Chelation Therapy (TACT) Grant Number 5 U01 AT001156-02 Progress Reports Part 3 2012-02-19: http://www.circare.org/tact/tact_progressreports_pt3.pdf
Trial to Assess Chelation Therapy (TACT) U01AT001156 FCOI Nahin, R. Letter to Paul Katz, M.D., Mount Sinai Medical Center RE: MSMC Financial Conflict of Interest Policies 2004-03-23: http://www.circare.org/tact/U01AT001156_fcoi_20040323.pdf
Trial to Assess Chelation Therapy (TACT) 7U01HL092607 Audit Response Lamas, G.A. Memo RE: Medicaid Audit of TACT Investigator Dr. Zbigniew Grudzien, M.D. 2011-03-14: http://www.circare.org/tact/7U01HL092607_audit_response_20110314.pdf
Trial to Assess Chelation Therapy (TACT) AT001156 Financial Status Reports 2003-2009: http://www.circare.org/tact/at001156_tact_fsrs_2003_2009.pdf
Trial to Assess Chelation Therapy (TACT) U1AT001156A PMS Report 2002-2009 (2011-08-11): http://www.circare.org/tact/u1at001156a_tactpms_report_2002_2009.pdf
Trial to Assess Chelation Therapy (TACT) U1HL092607A PMS Report 2010 (2011-08-11): http://www.circare.org/tact/u1hl092607a_tact_pmsreport_2010.pdf
Trial to Assess Chelation Therapy (TACT) U1HL092607B PMS Report 2011 (2011-08-11): http://www.circare.org/tact/u1hl092607b_tact_pmsreport_2011.pdf
National Institutes of Health. Trial to Assess Chelation Therapy (TACT). Clinicaltrials.gov web site. Available from http://clinicaltrials.gov/show/NCT00044213. Revised March 20, 2007. Accessibility verified 2007-08-31.
National Center for Complementary and Alternative Medicine, National Institutes of Health. List of U.S. Study Sites for Chelation Therapy Study. National Institutes of Health web site. Available from http://nccam.nih.gov/chelation/studysite.htm. July 26, 2007. Accessibility verified 2007-08-31.
National Center for Complementary and Alternative Medicine, National Institutes of Health. List of Canadian Study Sites for Chelation Therapy Study. National Institutes of Health web site. Available from http://nccam.nih.gov/chelation/studysitecan.htm. April 9, 2007. Accessibility verified 2007-08-31.
National Institutes of Health. Roster of Participants, National Center for Complementary and Alternative Medicine Special Emphasis Panel ZAT1 K(02). Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/nccamsepZAT1K02_20020104.pdf. January 4, 2002. Accessibility verified October 27, 2005.
National Institutes of Health. EDTA Chelation Therapy for Coronary Artery Disease, RFA: AT-01-004. National Institutes of Health web site. Available from http://grants2.nih.gov/grants/guide/rfa-files/RFA-AT-01-004.html. April 30, 2001. Accessibility verified October 31, 2005.
National Institutes of Health. EDTA Chelation Therapy for Coronary Artery Disease, RFA: AT-01-004, with references. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/rfa_AT-01-004.pdf. Undated. Accessibility verified October 31, 2005.
Lamas GA. Clinical Trial Protocol for grant application RFA: AT-01-004, Trial to Assess Chelation Therapy. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/tactprotocol_20010829.pdf. August 29, 2001. Accessibility verified October 31, 2005.
Lamas GA. Consent Form, Trial to Assess Chelation Therapy (TACT). Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/tactconsentform_20030113.pdf. January 13, 2003. Accessibility verified October 27, 2005.
Lamas GA. Clinical Trial Protocol, Trial to Assess Chelation Therapy (TACT). Version 2, pp. 1-53. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/tactprotocolv2_20030530.pdf. May 30, 2003. Accessibility verified January 18, 2006.
Lamas GA. Clinical Trial Protocol, Trial to Assess Chelation Therapy (TACT). Version 2, pp. 54-93. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/tactprotocolv2b_20030530.pdf. May 30, 2003. Accessibility verified January 18, 2006.
Lamas GA. Consent Form, Trial to Assess Chelation Therapy (TACT). Version 2. Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/tactconsentform_20030613.pdf. June 30, 2003. Accessibility verified October 27, 2005.
National Institutes of Health. Notice of Grants Awards Report. Number 1 U01 AT001156-01 (Revised). Trial to Assess Chelation Therapy (TACT). Citizens for Responsible Care and Research (CIRCARE) web site. Available from http://www.circare.org/tact/tactawardnotice_20030330.pdf. March 30, 2003. Accessibility verified January 18, 2006.
EDTA Chelation Therapy Proponent H. Ray Evers, M.D.
United States v. An Article of Drug *** Diso-tate, et al. United States District Court for the Eastern Division of Louisiana. No. 75-1790. September 28, 1976. Vincent A. Kleinfeld, Alan H. Kaplan & Stephen A. Weitzman. Federal Food, Drug, and Cosmetic Act Judicial Record 1975-1977 (FDLI, Washington, DC 1979). Citizens for Responsible Care and Research (CIRCARE) web site. Accessed on 2006-11-09 at: http://www.circare.org/tact/17-1790_19760928.pdf
453 F. Supp. 1141. United States of America v. H. Ray Evers, M. D., an Individual, doing business as Ra-Mar Clinic. Civ. A. No. 78-93-N. United States District Court Middle District of Alabama, Northern Division. June 27, 1978. Accessed on 2006-11-09 at: http://www.circare.org/foia2/evers.pdf
United States of America v. H. Ray Evers. Information for Corruptly Endeavoring to Interfere with Administration of Internal Revenue Laws and Intimidating and Impeding Officers of the Internal Revenue Service. CR No. 76-326. 1976-10-20. United States District Court Eastern District of Louisiana. Accessed on 2006-11-09 at: http://www.circare.org/foia2/evers_76-326_19761020.pdf
Evers HR. Agreement Between Physician and Patient Ra-Mar Clinic. Undated. Accessed 2006-09-28 at: http://www.circare.org/tact/evers_chelationagreement.pdf
Rorison D, Louisiana State Board of Medical Examiners. Letter to Robert McKim Bell. June 6, 1993-06-06. Accessed on 2006-11-09 at: http://www.circare.org/tact/rorison_bell19930603.pdf
Alabama Board of Medical Examiners vs. Herbert Ray Evers, M.D. Complaint and Petition for Revocation of License. 1985-11-25: http://www.circare.org/pd/eversalcomplaint_19851125.pdf
Alabama Board of Medical Examiners vs. Herbert Ray Evers, M.D. Order. 1986-12-17: http://www.circare.org/pd/eversalorder_19861217.pdf
Spence JD. Letter to Jerome J. Papke, Program Officer DHEW, Social Security Administration Bureau of Health Insurance re: Meadowbrook Hospital, Belle Chasse, LA. 1975-12-29. Accessed on 2006-11-09 at: http://www.circare.org/foia2/spence_wrtnrpt_19751229.pdf
Spence JD. Letter to W. Sherwood Lawrence, Medical Officer, California State Department of Health Food and Drug Section. 1976-07-09. Accessed on 2007-02-01 at: http://www.circare.org/foia2/spence_lawrence_19760709.pdf
Spence JD. Statement to the Assembly Health Committee of the California Legislature re: SB 1474 and 1475. 1976. Accessed on 2007-02-01 at: http://www.circare.org/foia2/spence_statementSB1474_1976.pdf
Errata
State Medical and Osteopathic Board Policies, Laws, and Regulation on EDTA Chelation Therapy: http://www.circare.org/tact/state_policies.htm
Last Updated: 2013-04-21
Adobe® Reader :: ::
